Corpus Intelligence IC Memo — SHARP CHULA VISTA MEDICAL CENTER 2026-04-26 10:39 UTC
IC Memo — SHARP CHULA VISTA MEDICAL CENTER
Investment Committee Memorandum | CA | 349 beds | Grade C | EBITDA uplift $38.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SHARP CHULA VISTA MEDICAL CENTER

CCN 050222 | SAN DIEGO, CA | 349 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SHARP CHULA VISTA MEDICAL CENTER is a 349-bed suburban community hospital in SAN DIEGO, CA with $519.1M in net patient revenue and a -9.6% operating margin. The hospital serves a payer mix of 20.9% Medicare, 9.8% Medicaid, and 69.4% commercial.

Thesis: Undervalued. Our ML models identify $38.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -9.6% to -2.3% (+736bps).

Net Revenue HCRIS$519.1M
Current EBITDA COMPUTED$-50.0M
Operating Margin COMPUTED-9.6%
Occupancy HCRIS72.1%
Revenue / Bed COMPUTED$1.5M
Net-to-Gross HCRIS16.8%
Distress Probability ML43.1%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
155
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -9.6% places it below the state median. Among 155 size-comparable peers (174-698 beds), the median margin is -4.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (174-698), prioritizing same-state peers. 155 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SHARP CHULA VISTA MEDICAL CENT (Target)CA349$519.1M-9.6%
STANFORD HEALTH CARECA657$6.76B3.7%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $38.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$10.9M+210bp18mo
Cost to Collect4.5%2.5%$10.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$10.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.3M+122bp9mo
Clean Claim Rate88.0%96.0%$332K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$10.9M
Cost to Collect
$10.4M
Denial Rate Reduction
$10.3M
A/R Days Reduction
$6.3M
Clean Claim Rate
$332K
Total EBITDA Uplift$38.2M
Current EBITDA$-50.0M
+ RCM Uplift+$38.2M
Pro Forma EBITDA$-11.8M
Current Margin-9.6%
Pro Forma Margin-2.3%
WC Released (1x)$19.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-76.9M$52.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-76.9M$32.8M0.00x-100.0%
Bull Case9.0x11.0x$-69.2M$133.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-69.2M$125.7M0.00x-100.0%
Bear Case11.0x10.0x$-84.6M$-113.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-84.6M$-152.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 155 hospitals with 174-698 beds
  • Same-state prioritization (n=156)
  • Comp margins: P25=-15.9% / P50=-4.1% / P75=3.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.